menu
    • menu
    [{"orgOrder":0,"company":"Trevi Therapeutics","sponsor":"Stifel","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2021","type":"Private Placement","leadProduct":"Nalbuphine Hydrochloride","moa":"Opioid receptor","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Trevi Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0.01,"dosageForm":"Extended-release Tablet","sponsorNew":"Trevi Therapeutics \/ Stifel","highestDevelopmentStatusID":"9","companyTruncated":"Trevi Therapeutics \/ Stifel"},{"orgOrder":0,"company":"Trevi Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Nalbuphine Hydrochloride","moa":"Opioid receptor","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Trevi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Extended-release Tablet","sponsorNew":"Trevi Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Trevi Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Trevi Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Nalbuphine Hydrochloride","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Trevi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Trevi Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Trevi Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Trevi Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Nalbuphine Hydrochloride","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Trevi Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Trevi Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Trevi Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Devonian Health Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Thykamine","moa":"PDE","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Devonian Health Group","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Devonian Health Group \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Devonian Health Group \/ Not Applicable"},{"orgOrder":0,"company":"Devonian Health Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Thykamine","moa":"PDE","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Devonian Health Group","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Devonian Health Group \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Devonian Health Group \/ Not Applicable"},{"orgOrder":0,"company":"Legacy Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Coacillium","moa":"","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Legacy Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Legacy Healthcare \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Legacy Healthcare \/ Not Applicable"},{"orgOrder":0,"company":"AOBiome Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"B244","moa":"","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"AOBiome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"AOBiome Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"AOBiome Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Devonian Health Group","sponsor":"TSX Venture Exchange","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2023","type":"Private Placement","leadProduct":"Thykamine","moa":"","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Devonian Health Group","amount2":0.01,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0.01,"dosageForm":"Cream","sponsorNew":"Devonian Health Group \/ TSX Venture Exchange","highestDevelopmentStatusID":"9","companyTruncated":"Devonian Health Group \/ TSX Venture Exchange"},{"orgOrder":0,"company":"Devonian Health Group","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2023","type":"Private Placement","leadProduct":"Thykamine","moa":"","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Devonian Health Group","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Devonian Health Group \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Devonian Health Group \/ Undisclosed"},{"orgOrder":0,"company":"Legacy Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Coacillium","moa":"","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Legacy Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Legacy Healthcare \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Legacy Healthcare \/ Not Applicable"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Difelikefalin","moa":"","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"CARA Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"CARA Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"CARA Therapeutics \/ Not Applicable"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            CARA Therapeutics

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            CARA Therapeutics

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Difelikefalin

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Cara Therapeutics: Outcome of KOURAGE-1 Study on Oral Difelikefalin in Notalgia

                            Details : Korsuva (difelikefalin) is a kappa opioid receptor agonists. Its oral formulation is under development for the treatment of moderate-to-severe pruritus in adult patients with notalgia paresthetica.

                            Brand Name : Korsuva

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            June 12, 2024

                            Lead Product(s) : Difelikefalin

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Acelyrin

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Acelyrin

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Izokibep

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ACELYRIN, INC. Announces Top-Line Results from Placebo-Controlled Clinical Trial of Izokibep for Moderate-to-S...

                            Details : IMG-020 (izokibep) is a small therapeutic protein inhibitor of interleukin-17A (IL-17A). It is designed to overcome monoclonal antibodies limitations for hidradenitis suppurativa indication. It is being investigated for moderate-to-severe Hidradenitis.

                            Brand Name : IMG-020

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            September 11, 2023

                            Lead Product(s) : Izokibep

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Legacy Healthcare

                            Switzerland arrow
                            2024 ACI Convention
                            Not Confirmed

                            Legacy Healthcare

                            Switzerland arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Coacillium

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Legacy Healthcare Announces EMA Validation of Marketing Authorisation Application (MAA) for Coacillium for the...

                            Details : LH-8 (coacillium) is an investigational botanical drug and is the first and only drug candidate for alopecia areata in children and adolescents with both moderate and severe forms of the disease.

                            Brand Name : LH-8

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 19, 2023

                            Lead Product(s) : Coacillium

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Devonian Health Group

                            Canada arrow
                            2024 ACI Convention
                            Not Confirmed

                            Devonian Health Group

                            Canada arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Thykamine

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : $1.2 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Devonian Announces Closing of a Private Placement of $1.2 Million

                            Details : The proceeds will fund the preparation of clinical study programs for PUR0110 (thykamine) in phase 2/3 program of pediatric atopic dermatitis, phase 2 programs of radiodermatitis associated with radiotherapy and in Hand and Foot Syndrome and associated w...

                            Brand Name : PUR0110

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            June 06, 2023

                            Lead Product(s) : Thykamine

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : $1.2 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Acelyrin

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Acelyrin

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Izokibep

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Morgan Stanley

                            Deal Size : $621.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Acelyrin, Inc. Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option ...

                            Details : Company will use the proceeds to fund its operations, including the development of pipeline including Izokibep and commercialization activities, business development activities, and capital expenditures.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            May 09, 2023

                            Lead Product(s) : Izokibep

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Morgan Stanley

                            Deal Size : $621.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Acelyrin

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Acelyrin

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Izokibep

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Morgan Stanley

                            Deal Size : $540.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            ACELYRIN, INC. Announces Pricing of Upsized Initial Public Offering

                            Details : The net proceeds will be used to advance the clinical development of izokibep through topline data in Phase 2b/3 trials of izokibep in each of HS, PsA, and uveitis.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            May 04, 2023

                            Lead Product(s) : Izokibep

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Morgan Stanley

                            Deal Size : $540.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            AOBiome Therapeutics

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            AOBiome Therapeutics

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : B244

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            AOBiome Therapeutics Granted Composition of Matter Patent for its Clinical Candidate B244

                            Details : B244 platform is a patented, proprietary, topical formulation. Once deployed, B244 produces nitric oxide, a signaling molecule known to regulate inflammation and vasodilation. It has shown clinical significance for atopic dermatitis and associated prurit...

                            Brand Name : B244

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            April 06, 2023

                            Lead Product(s) : B244

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Legacy Healthcare

                            Switzerland arrow
                            2024 ACI Convention
                            Not Confirmed

                            Legacy Healthcare

                            Switzerland arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Coacillium

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Legacy Healthcare Announces Positive Top-Line Results from Phase 2/3 Trial of Coacillium Cutaneous Solution, t...

                            Details : LH-8 (coacillium) is an investigational topical botanical drug. Drug interrupts the immuno-inflammatory reactions and their deleterious consequences on hair follicles and adjacent dermal tissues via a pleiotropic mechanism.

                            Brand Name : LH-8

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 06, 2023

                            Lead Product(s) : Coacillium

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            180 Life Sciences

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            180 Life Sciences

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Adalimumab

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Alliance Global Partners

                            Deal Size : $6.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            180 Life Sciences Corp. Announces Closing of $6 Million Registered Direct Offering Priced At-The-Market Under ...

                            Details : Adalimumab is a monoclonal anti-tumor necrosis factor alpha antibody used in the treatment of a wide variety of inflammatory conditions such as rheumatoid arthritis, crohn's disease, and ankylosing spondylitis.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            December 23, 2022

                            Lead Product(s) : Adalimumab

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Alliance Global Partners

                            Deal Size : $6.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            180 Life Sciences

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            180 Life Sciences

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Adalimumab

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Alliance Global Partners

                            Deal Size : $6.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            180 Life Sciences Corp. Announces $6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rule...

                            Details : Research at Oxford University has indicated an anti-TNF mechanism of Adalimumab can slow or prevent the proliferation of myoblast cells that lead to the formation and growth of the fibrous nodules/cords in the palm and possible finger contracture.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            December 20, 2022

                            Lead Product(s) : Adalimumab

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Alliance Global Partners

                            Deal Size : $6.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth